![Page 1: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/1.jpg)
BIOTECH SUPPLYBIOTECH SUPPLYBIOTECH SUPPLYBIOTECH SUPPLYOctober 8-9, 2012
Crowne Plaza, Foster City, CA
Tufts CSDD Global Clinical Supply Chain Market Study
Mary Jo Lamberti, PhD Senior Project Manager
Tufts CSDD
![Page 2: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/2.jpg)
Key Areas Explored in Study
• Roles and responsibilities• Technology and use of resources• Management challenges & strategy• Outsourcing approaches• Future Outlook
![Page 3: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/3.jpg)
Study Highlights Overview
• Timely study capturing major shift in sponsor clinical supply chain management practices
• Transition of role from insulated, support function to a more strategic, multi-disciplinary front-line function
» Increasing importance of forecasting and risk management» Cross functional collaboration and coordination
• Growing receptivity to outsourcing
• Baseline measures of practices and key challenges
3
![Page 4: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/4.jpg)
Methods
• Tufts CSDD developed online survey with input from supply chain experts in industry and provider organizations
• Survey distributed through contacts and mailing lists in Jan-Feb 2011
• Roundtable Meeting of invited participating companies held in mid-March
![Page 5: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/5.jpg)
Survey Respondents
• 20 completed surveys
• Primarily large/mid-size biopharma companies
• Majority (80%) vice president/director level
• Median 20 years experience in biopharma industry– Minimum of 3 years
• Median 3.5 years in current position– Minimum of 1 year
![Page 6: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/6.jpg)
Global Clinical Supply Chain Market Roundtable
• 12 senior-level clinical supply management professionals from top biopharma companies in March 2011 in Boston
• Very participatory group – corroborated and added to survey findings and interpretation; interest in forming an ongoing working group
• Supply management role is evolving from insular/traditional role into a strategic function with far more cross-functional coordination and collaboration
• Clinical supply management is becoming increasingly complex and demanding—given time pressures and global logistics challenges
• More sophisticated forecasting and risk-management becoming critical capabilities
![Page 7: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/7.jpg)
Primary Responsibilities
Responsibility % of Respondents
Forecasting 95%
Manage supplier relationships 85%
Track supplier performance metrics 70%
Supplier assessment/selection 65%
Develop outsourcing strategy 60%
Develop contracts 50%
Negotiate contracts 40%
Other* 20%
* Other responsibilities include supply management and IVRS management
![Page 8: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/8.jpg)
Technology Usage
Study Drug Forecasting•Respondents use both manual approaches (70%) and forecasting programs (75%)•More than half reported using web-based approaches•Respondents indicated that the most demanding resource requirement area is forecasting supplies
![Page 9: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/9.jpg)
Barriers to Implementing New Technologies
• Cost (both dollars and resources)
• Difficulty integrating new and existing systems
• Lack of standards between systems
![Page 10: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/10.jpg)
Most Demanding Resource Requirement Areas
![Page 11: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/11.jpg)
Top Ranked Clinical Supply Chain Management Challenges
1. Short lead times
2. Operations-supply team communication
3. Protocol readiness/accuracy
4. Better forecasting
5. Visibility
![Page 12: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/12.jpg)
Top Factors Impacting Clinical Supply Chain Strategy
1. Increasing number of trials
2. Globalization of trials
3. Regulatory requirements
4. Adaptive trial designs
5. Mergers and acquisitions
![Page 13: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/13.jpg)
Top Factors Impacting Clinical Supply Chain Management Success
• Shorter study start-up timelines
• Study site locations
• Increasing number of study subjects
• Shorter development timelines
![Page 14: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/14.jpg)
Factors Impacting Clinical Supply Chain Management Success
![Page 15: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/15.jpg)
Top Clinical Supply Priorities in 2011
1. Improve forecasting
2. Establish Preferred Provider partnerships
3. Reduce operating costs
![Page 16: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/16.jpg)
Frequency of Activities Outsourced
![Page 17: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/17.jpg)
Strategies to Optimize Clinical Supply Chain Management
% of Respondents
Functional outsourcing 60%
Tactical/study-specific outsourcing 60%
Regional hubs 65%
New technologies 40%
Investing in own capabilities,such as adding owned depots 20%
Other* 20%
*Other strategies include drug pooling, IVR capabilities, and labeling
![Page 18: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/18.jpg)
Outsourcing Relationships Used
Strategy % of RespondentsIndividual clinical supply services for each trial 58%
A full range of clinical supply services to aprovider for each trial 16%
A service provider to manage the entire clinicalsupply function across multiple clinical trials 16%
A combination of types depending on the trial 11%
![Page 19: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/19.jpg)
Metrics Used to Assess Clinical Supply Vendor Relationship Quality
![Page 20: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/20.jpg)
Metrics Used to Assess Clinical Supply Solution Success
![Page 21: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/21.jpg)
Initiatives Underway
Comparator and Co-Therapy Sourcing Roundtables
•Follow up meetings held in Boston in October 2011 and London in March 2012•20 senior level managers from 15 top biopharma companies attended each meeting•Meeting focused on Issues and challenges in comparator and co-therapy sourcing•Next steps included plans for industry collaboration and dissemination of best practices
![Page 22: BIOTECH SUPPLY October 8-9, 2012 Crowne Plaza, Foster City, CA Tufts CSDD Global Clinical Supply Chain Market Study Mary Jo Lamberti, PhD Senior Project](https://reader035.vdocument.in/reader035/viewer/2022062515/56649d205503460f949f4295/html5/thumbnails/22.jpg)
Initiatives Underway
Comparator and Co-Therapy Working Group Study
•Tufts CSDD 2012 Study
•Multi-sponsor format; conducted between April/May and December 2012
•Key metrics:• Growing proportion of comparator and co-therapy use in protocol designs• Total amount spent on comparators and co-therapies between 2009 and 2012 (estimates)• Comparative increase in cost relative to per patient costs per protocol, procedural costs per
protocol, other clinical supplies• Total amount of comparator and co-therapy drug not used and estimated economic cost of
waste